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Abstract
Genetic case-control association studies often include data on clinical covariates, such as body mass index (BMI), smoking
status, or age, that may modify the underlying genetic risk of case or control samples. For example, in type 2 diabetes, odds
ratios for established variants estimated from low–BMI cases are larger than those estimated from high–BMI cases. An
unanswered question is how to use this information to maximize statistical power in case-control studies that ascertain
individuals on the basis of phenotype (case-control ascertainment) or phenotype and clinical covariates (case-control-
covariate ascertainment). While current approaches improve power in studies with random ascertainment, they often lose
power under case-control ascertainment and fail to capture available power increases under case-control-covariate
ascertainment. We show that an informed conditioning approach, based on the liability threshold model with parameters
informed by external epidemiological information, fully accounts for disease prevalence and non-random ascertainment of
phenotype as well as covariates and provides a substantial increase in power while maintaining a properly controlled false-
positive rate. Our method outperforms standard case-control association tests with or without covariates, tests of gene x
covariate interaction, and previously proposed tests for dealing with covariates in ascertained data, with especially large
improvements in the case of case-control-covariate ascertainment. We investigate empirical case-control studies of type 2
diabetes, prostate cancer, lung cancer, breast cancer, rheumatoid arthritis, age-related macular degeneration, and end-stage
kidney disease over a total of 89,726 samples. In these datasets, informed conditioning outperforms logistic regression for
115 of the 157 known associated variants investigated (P-value=1610
29). The improvement varied across diseases with a
16% median increase in x
2 test statistics and a commensurate increase in power. This suggests that applying our method to
existing and future association studies of these diseases may identify novel disease loci.
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Introduction
Genetic risk in case-control studies often varies as a function of
body mass index (BMI), age or other clinical covariates. For
example, in a recent type 2 diabetes study, 23 of 29 established
associated SNPs had higher odds ratios when estimated from low-
BMI cases than from high-BMI cases (average odds ratios 1.182
versus 1.128) [1]. Higher genetic risk in early-onset cases has been
shown empirically for prostate and breast cancers [2,3], and has
also been hypothesized for other diseases [4,5]. Covariates such as
smoking status may affect genetic risk in several diseases including
lung cancer [6], and information on these covariates may alter the
expected level of genetic risk carried by a case (or control) sample.
The question of how to optimally incorporate these covariates in
case-control association studies is a function of the study design.
We divide the set of possible study designs into three classes,
random ascertainment (cohort or cross-section designs), case-
control ascertainment that ascertains individuals based on
phenotype, and case-control-covariate ascertainment that ascer-
tains on both phenotype and clinical covariate (as in age-matched
studies). When individuals are randomly ascertained, conditioning
on covariates associated with phenotype can increase study power
by reducing phenotypic variance [7]. It is well known that
conditioning on covariates in ascertained data can result in a
dramatic loss in power [8,9,10,11] , and several approaches to
address this issue in case-control studies have previously been
described [12,13,14]. In addition, a paper just published in Nature
Genetics [15] has made a valuable contribution by highlighting this
issue for both genetic covariates and a clinical covariate (gender) in
case-control studies, although that paper did not propose a new
method to solve this important problem. Matched case-control-
covariate ascertainment is commonly used as a means of
preventing ascertainment induced power loss by matching the
covariate distribution in cases and controls [13], but standard
conditioning provides no gain in power in this case [16]. show that
another type of case-control-covariate ascertainment, oversam-
pling low-risk (low-BMI) cases and high-risk (high-BMI) controls
can increase power with standard association tests, but standard
statistical tests may not capture all of the available power increase.
As we show below, previous approaches such as logistic or linear
regression (Armitage trend test [17]) with or without covariates,
marginal or joint tests of gene x covariate interaction [18,19],
comparing early-onset cases to controls [5,20], analyzing cases
only [21], and a semi-parametric approach designed to address
case-control ascertainment issues [12], all fail to capture the
increase in statistical power that is available when there exists
external epidemiological data describing disease prevalence as a
function of the covariate. Some of these previous methods lose
power under case-control ascertainment, and all fail to capture the
available power gain under case-control-covariate ascertainment.
Here, we investigate a new approach to estimating the
parameters of the liability threshold (LT) model [22], a classical
modeling approach that has recently been used in studies of
heritability and risk prediction [23,24,25]. Previously, we devel-
oped a parameter estimation method for the LT model in the case
of genetic covariates (known associated variants) for which samples
are randomly ascertained, and showed that it improved power
relative to logistic regression with or without conditioning [26]. In
this work, we develop a new parameter estimation method for
studies with randomly or non-randomly ascertained clinical covari-
ates that leverages the epidemiological literature to fit LT
parameters. By estimating covariate effect sizes externally from
the case-control study data this approach prevents ascertainment-
induced power loss, while maintaining the power gain achieved by
reducing phenotypic variance. We show by simulation that our
approach to fitting liability threshold models and computing case-
control association statistics outperforms previously developed
approaches. Our method produces a large improvement in power
under case-control-covariate ascertainment, a study design that
previous methods do not address [12,13,17,26]. Our method also
outperforms previous methods under case-control ascertainment,
because covariate effect sizes can be estimated more accurately
using external epidemiological information. We demonstrate both
analytically and empirically that our association statistic produces
the correct null distribution.
We apply the method to empirical case-control ascertained and
case-control-covariate ascertained studies for seven different
diseases: type 2 diabetes, prostate cancer, lung cancer, post-
menopausal breast cancer, rheumatoid arthritis, age-related
macular degeneration, and end-stage kidney disease over a total
of 89,726 samples. Our method uses published prevalence data (as
a function of clinical covariates) for each disease to estimate the LT
parameters. The published prevalence data are an external source
of information not utilized by the other statistical tests.
In these datasets, which include case-control and case-control-
covariate designs, informed conditioning outperforms marginal
logistic regression for 115 of the 157 known associated variants
investigated (P-value=1610
29) with a 16% median increase in x
2
test statistic and a commensurate increase in power, attaining a
substantial and highly statistically significant improvement in
association statistics. We conclude that application of informed
conditioning to future case-control-covariate ascertained and case-
control ascertained association studies of these diseases, or other
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genetic risk, has the potential to substantially increase the power of
disease gene discovery.
Methods
Liability threshold model
The model is defined by Q~
X J
j~1
cj(tj{ t tj)zmze, where
e=cg+N(0,1), and an individual is a disease case (z=1) if and
only if Q$0 and is a control otherwise (z=0) [22]. Here Q is an
unobserved underlying quantitative trait called the liability. The cj
parameters quantify the effect of each covariate on the liability
scale and m is an affine parameter that determines the disease
prevalence at the covariate means t tj by f~W({m), where W is the
normal cumulative distribution function and W({m) is P(x.2m).
For diseases with prevalence less than 50% m will be negative. tj is
the value of covariate j, t tj is the population mean of covariate j, g is
the genotype of the candidate SNP (normalized to mean 0), c is the
effect size (equal to 0 under the null model) and N(0,1) is the
standard normal distribution. The proportion of variance
explained by covariate j on the liability scale is
(cj:sj)
2
1z
P
j
(cj:sj)
2
where sj is the standard deviation of covariate j.
Overview of method
Our method employs a three-step procedure. First, we fit the
parameters cj and m via a method (LTPub) that uses published
prevalence information. Second, we compute the posterior mean
residual liability E(eDz,t) for each individual given the case-control
status z and the values of the clinical covariates t. Missing
covariates in cases are assigned the mean value of the covariate in
cases and similarly for controls. Third, we perform linear
regression of the posterior mean residual liability against the
genotypes of the SNPs we wish to test while optionally
incorporating additional covariates such as principal components
(PCs), generalizing the EIGENSTRAT method [27]. Each of
these steps is described in detail below. All methods described here
are implemented in the LTSOFT software (see Web Resources).
We note that there are important differences between our statistic
and existing statistics such as those currently implemented in R
(see Text S1 in File S1).
The approach is best illustrated by an example. We consider a
simulated BMI-matched case-control-covariate type 2diabetes(T2D)
dataset. In T2D, prevalence is greater in the population of individuals
with high BMI. Our toy example contains 3,000 cases and 3,000
controls, half with BMI=24 and half with BMI=35. (This gives a
mean BMI of 29.5 and standard deviation of 5.5, similar to the real
T2D studies analyzed below.) We first fit the parameters of the
liability threshold model using published information on prevalence
as a function of BMI. This procedure is described in detail below and
gives a liability model Q=c(t2 t t)+m+e where c=0.08, m=21.44,
 t t=26.5, e=cg+N(0,1). We choose c=0.1 and give g am i n o ra l l e l e
frequency of 0.5. In this case t is BMI and  t t is the mean BMI. The
parameter c is the coefficient of BMI in liability model. An individual
is disease case if Q$0 and a control if Q,0.
We next compute the posterior mean value of the residual
quantitative trait adjusted for BMI according to equations (1) and
(2) below (Figure 1 and Table 1). Since the liability Q and e are
normally distributed, the posterior distribution of e is the tail of
normal. In Figure 1 this distribution is shown for the low-BMI and
high-BMI cases. A BMI=24 T2D case has a more extreme
posterior mean value of e, (2.09) than a BMI=35 T2D case (1.37),
because for BMI=24 the lower contribution from BMI implies
that a larger contribution from other factors (e.g. genetic factors) is
needed to exceed the liability threshold. Similarly, a BMI=35
T2D control has a slightly more extreme value (20.36) than a
BMI=24 T2D control (20.10), in order to stay below the liability
threshold despite the higher contribution from BMI. In contrast,
in standard linear regression all cases have the same value (e.g. 1)
and all controls have the same value (e.g. 0).
We test a causal variant with minor allele frequency (maf) 0.5 in
the population and an effect size on the liability scale of c=0.1
corresponding to an estimated odds ratio of 1.25 in the BMI=24
cases and 1.16 in the BMI=35 individuals (see Simulations). We
compute association statistics for the liability threshold (LT) model
using these posterior mean values (Table 1). Our LT statistic is a
score test equivalent to a linear regression likelihood ratio test
where the alternate likelihood is the likelihood of the posterior
mean of the residual of the liability (E(e|z,t)) under a linear
regression model with an unconstrained genotype effect size.
Under the null the genotype effect size is equal to 0.
In these simulations, the likelihood ratio test has an expected x
2(1
dof)=30.3 (P=3.761028), which is genome-wide significant. It is
notable that applying logistic regression (LogR) directly to case-
control phenotypes produces a less significant statistic—either with
or without conditioning on BMI, which has virtually no effect since
cases and controls are BMI-matched. Logistic Regression of case-
control status against genotype has an expected x
2(1 dof)=27.9
(P=1.361027), and an expected x
2(1 dof)=27.9 (P=1.361027)
when using BMIas a covariate. Neither of these statistics is genome-
wide significant. Studies with case-control-covariate ascertainment
often attempt to match on a covariate, such as BMI in this example
in order to prevent a loss of power that can come from stratified
testing [13]. While it is true that the conditioned logistic regression
test did not lose power relative to logistic regression, neither test
obtained the power available to the LT statistic. This is because
when there is no difference in the distribution of BMI between cases
and controls logistic regression and other previous approaches
[12,13,17,26] will set the effect size of BMI to 0, while the LT
statistic uses external epidemiological information to estimate the
effect size of BMI.
Author Summary
This work describes a new methodology for analyzing
genome-wide case-control association studies of diseases
with strong correlations to clinical covariates, such as age
in prostate cancer and body mass index in type 2 diabetes.
Currently, researchers either ignore these clinical covari-
ates or apply approaches that ignore the disease’s
prevalence and the study’s ascertainment strategy. We
take an alternative approach, leveraging external preva-
lence information from the epidemiological literature and
constructing a statistic based on the classic liability
threshold model of disease. Our approach not only
improves the power of studies that ascertain individuals
randomly or based on the disease phenotype, but also
improves the power of studies that ascertain individuals
based on both the disease phenotype and clinical
covariates. We apply our statistic to seven datasets over
six different diseases and a variety of clinical covariates. We
found that there was a substantial improvement in test
statistics relative to current approaches at known associ-
ated variants. This suggests that novel loci may be
identified by applying our method to existing and future
association studies of these diseases.
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We begin with published prevalence information over a range
of values of clinical covariates. One means of finding the liability
threshold parameters to minimize the normalized least-squares
error
X
j
X
tj
fcj,m(tj){f(tj)
fcj,m(tj)zf(tj)
 ! 2
where fcj,m(tj)~W({cj(tj{ t tj){m) is prevalence at covariate value
tj under the liability threshold model with parameters cj and m,a n d
f(tj) is the published prevalence at value tj. For example, prostate
cancer is known to have prevalence 2%, 8%, 14% for individuals of
age 60, 70, 80, respectively (f(60)~0:02, f(70)~0:08, f(80)~0:14)
(see Text S1 in File S1). In this case, the parameters c1 =0.05and
m=22.5 imply prevalence values of 2%, 7%, 16% for individuals of
age 60, 70, 80 (based on standard normal probabilities for e$2.0,
e$1.5, e$1.0 under the null model c=0, and a mean age of 50). In
order to avoid the binary search procedure we transform the search
from the disease scale to the liability scale minimizing
X
j
X
tj
{cj(tj{ t tj){m{W{1f(tj)
   2
Figure 1. Illustration of liability threshold model: simulated T2D example. The posterior mean of e for low-BMI and high-BMI cases is the
expected value of e given that it exceeds c(t2 t t)+m. High-BMI cases have a lower posterior mean relative to low-BMI cases since they require a smaller
contribution from genetics to exceed the threshold in the liability threshold model.
doi:10.1371/journal.pgen.1003032.g001
Table 1. Illustration of liability threshold model: simulated
T2D example.
Posterior mean E(e|z,t) Allele frequency
Cases, BMI=24 2.09 0.55
Cases, BMI=35 1.37 0.53
Controls, BMI=24 20.10 0.50
Controls, BMI=35 20.36 0.49
Posterior mean value of residual quantitative trait e (adjusted for BMI) as a
function of BMI and case-control status. We also list allele frequencies specified
in simulated genotype data.
doi:10.1371/journal.pgen.1003032.t001
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fact that some individuals will die before age ti is irrelevant to our
computations, since the liability threshold model is defined for
individuals who are alive at a given age t.T h em e a n t t was chosen as
the mean from the available prevalence data, and mis-specifying the
m e a nh a sl i t t l ee f f e c t( s e eT e x tS 1a n dT a b l eS 1i nF i l eS 1 ) .F o re a c h
disease studied, the source of prevalence data for each covariate is
g i v e ni nT e x tS 1i nF i l eS 1 .
When there are multiple covariates we treat them as indepen-
dent but infer the parameters jointly. For example, in T2D we fit
the parameters c1 for age, c2 for BMI, and m (the affine term)
simultaneously. We believe that this is a reasonable approximation
so long as the covariates are only weakly correlated, as association
statistics are robust to small deviations in model parameters (see
below). When clinical covariates are highly correlated, treating
them as independent will reduce power. It is possible to avoid this
power loss by fitting the LT model with prevalence data for both
covariates simultaneously (e.g. specifying the prevalence of T2D at
all age/BMI pairs). For the datasets in this study, this was not
necessary, as the squared correlation was less than 0.026 for all
pairs of covariates.
Association test using posterior mean value of
underlying quantitative trait
The main idea is that instead of conducting an association test
using case-control phenotype z, we use the posterior mean E(eDz,t)
of the (unobserved) residual liability e. Thus,
E(ejz,t)~
ð ?
{c(t{ t t){m
e
1
ﬃﬃﬃﬃﬃﬃ
2p
p exp
{e2
2
  
de
, ð ?
{c(t{ t t){m
1
ﬃﬃﬃﬃﬃﬃ
2p
p exp
{e2
2
  
de if z~ 1,
ð1Þ
E(ejz,t)~
ð {c(t{ t t){m
{?
e
1
ﬃﬃﬃﬃﬃﬃ
2p
p exp
{e2
2
  
de
, ð {c(t{ t t){m
{?
1
ﬃﬃﬃﬃﬃﬃ
2p
p exp
{e2
2
  
de if z~ 0:
ð2Þ
When a study measures age at onset, or age and other covariates at
onset, then the precise point at which the threshold is crossed is
known, and E(eDz,t)={c(t{ t t){m can be used. Our association
statistic is a measure of association between genotype g and
posterior mean residual liability E(eDz,t) across samples. We treat
E(eDz,t) as a continuous variable and perform linear regression,
computing the number of samples times the squared correlation
between g and E(eDz,t), employing a generalized Armitage trend
test [17], and generalizing EIGENSTRAT if PC covariates are
also used [27,28]. Although E(eDz,t) is not normally distributed,
the use of linear regression as opposed to logistic regression is
accepted practice in association studies [17,27,28]. Effect sizes are
returned on the liability scale and these can easily be converted to
odds ratios if desired (e.g. for meta-analysis) (see Text S1 in File
S1).
We show below that this is equivalent to the Score test, which is
also commonly used in genetic association studies [1,29,30]. We
write the prospective likelihood as a function of effect size c is
L(c)~ P
i
ð Ui
Li
1
ﬃﬃﬃﬃﬃﬃ
2p
p exp
{(e{cgi)
2
2
 !
de
2
6 4
3
7 5,
where Li~{c(ti{ t t){m,Ui~? for cases and Li~{?,Ui~{
c(ti{ t t){m for controls. Thus,
Llog L(c)
Lc
  
c~0
~
X
i
ð Ui
Li
egi
1
ﬃﬃﬃﬃﬃﬃ
2p
p exp
{e2
2
  
de
,ð Ui
Li
1
ﬃﬃﬃﬃﬃﬃ
2p
p exp
{e2
2
  
de~
X
i
giE(eDzi,ti):
follows that the Score statistic is equal to the square of
X
i
gi
E(eDzi,ti) divided by its empirical variance, which is equivalent to
the liability threshold statistic and has the correct null distribution.
The retrospective likelihood is equal to this prospective likelihood
(see Text S1 in File S1). We show below that this statistic is robust
to parameter mis-estimation and maintains the correct null
distribution (see Results).
Results
Simulations
We generalized the simulations from the toy case-control-
covariate example for T2D above. These simulations used a BMI-
matched design, which is a special case of case-control-covariate
ascertainment. For each effect size c between 0.00 and 0.15, we
simulated independent datasets using the liability threshold model
with a single clinical covariate with parameters c=0.08 and
m=21.44. We refer to the clinical covariate as BMI, but the
simulations apply equally to other clinical covariates. We assumed
3,000 cases and 3,000 BMI-matched controls, half with BMI=24
and half with BMI=35. We considered a SNP with allele
frequency p=0.50 in the general population. The estimated odds
ratio of the SNP increases with the effect size, and the estimated
odds ratio of individuals with BMI=24 is larger than the
estimated odds ratio of individuals with BMI=35 for every non-
zero effect size, consistent with Table 1. This is expected under the
LT model since cases with BMI=24 will generally need more risk
alleles to reach Q$0. For each value of c, we simulated 1,000,000
independent datasets using pcase,24, pcontrol,24, pcase,35, pcontrol,35
based on the liability threshold model. Using these simulations, we
evaluated power and false-positive rate. We also considered non-
additive models, as well as the effect of mis-specifying the
parameters of the LT model.
Evaluation of power
We considered five different statistical tests: logistic regression
(LogR) using case-control phenotype, LogR using case-control
phenotype with BMI as covariate (LogR+Cov), a x
2(2 dof) test for
main genetic effect and gene x BMI interaction (G+GxE) [18,19],
LogR comparing low-BMI cases to controls (LogRSub) [5,20],
and our association statistic (LT) using posterior mean residual
liability from the LT model (see Methods). We note that the x
2(2
dof) statistic (G+GxE) is a likelihood ratio test comparing the null
model of no main genetic effect and no gene x BMI interaction to
the causal model with main genetic effect and gene x BMI
interaction.
For each test, the average x
2 statistic is displayed in Table 2. We
see that the LT statistic produces an average improvement of 8.8%
in x
2 statistics compared to LogR. The improvement is a function
It
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frequency, and study design. The G+GxE test loses power due to
the extra degree of freedom. The LogRSub test performs nearly as
well as the LogR test, showing that low-BMI cases contribute more
power than high-BMI cases.
In addition to these five main tests we considered two additional
tests: A x
2(1 dof) statistic, which compares the null model of main
genetic effect only to the causal model with main genetic effect and
gene x BMI interaction, and is equal to the difference between
G+GxE and LogR statistics; a case-only logistic regression
comparing BMI=24 to BMI=35 [21]. These gene-environment
interaction tests had x
2(1 dof) statistics less than 5.0 for all effect
sizes and are not considered further. Another approach, probit
regression [31], uses an underlying model which is equivalent to
the liability threshold model. However, probit regression does not
account for disease prevalence, the effect sizes of covariates
estimated from the epidemiological literature, or the ascertainment
scheme used by the study and therefore produces very different
statistics from the LT model (see Text S1 in File S1). Probit and
linear regression gave similar results to logistic regression over all
simulations and real datasets. This result was obtained both with
and without covariates.
Average x
2 statistics are useful for comparison purposes, but do
not provide a formal assessment of power. We also performed
power calculations, computing the proportion of 1,000,000
simulations achieving the conventional GWAS cutoff for signifi-
cance at 5% level following correction for multiple testing of
P,5610
28. Results for a subset of methods are displayed in
Figure 2, indicating a 23% improvement in power for the LT
statistic. In all simulations the percent improvement in power is
substantially larger than the percent improvement in average x
2
statistic. We caution that these results will vary as a function of the
ascertainment of BMI in the study. Furthermore, for any choice of
ascertainment strategy, these results may overstate the prospects
for improvement in real data, since simulated data and association
statistics were based on the same model and model parameters.
We repeated the above experiments under a range of
ascertainment schemes (random, case-control, case-control-covar-
iate) and effect sizes (see Text S1 and Table S2 in File S1). In all
experiments the LT statistic matched or outperformed all of the
other statistical tests while maintaining the correct null distribu-
tion. For randomly ascertained studies, there is no induced
correlation between genotype and clinical covariate and we do not
expect or observe an improvement in our method over the others
[7]. In many cases conditioning on BMI significantly decreased
power. Under case-control ascertainment strategies, covariates
correlated with case-control status will also be correlated with
associated genotypes [10]. Conditioning on these covariates can
therefore introduce biases and reduce power [9,10,11] as a
function of covariate effect size and disease prevalence (see Text
S1 and Table S3 in File S1). Our method performs better than
previous approaches including [12] (see below), because covariate
effect sizes can be estimated more accurately using external
epidemiological information. Matched case-control-covariate de-
signs, in which covariates are matched in some proportions
between cases and controls, may prevent conditioning from having
any effect in existing methods. Since the LT statistic uses
information from external epidemiological literature it can still
produce an improvement.
False-positive rate and correct null distribution
To investigate the properties of the LT statistic under the null
we computed the mean value in the simulations above when
c=0.0. As seen in Table 2 this has the correct value of 1.00. In
addition it has the correct median, with lGC~1.00, 5.00% of tests
with P-value,0.05 and 1.00% of tests with P-value,0.01. We
applied Kolmogorov-Smirnov test [31] to determine if the LT
statistic differed significantly from a x
2 (1 dof) distribution. The
two-tailed K-S test of the full distribution was not significant (P-
value=0.34), nor was the K-S test restricted to the tail where the
LT statistic had x
2.3.84 (P-value=0.21). In order to further
investigate the extreme tail of the distribution we ran 10
8 tests
under the null and verified that 98 of the 10
8 tests (10
26) had a P-
value,10
26. The LT statistic is a score test when the parameters
are estimated correctly and will therefore have the correct null
distribution. We investigated the properties of the LT statistic
when the parameters were severely mis-estimated and found no
inflation (see Text S1 in File S1). Furthermore, since the LT
statistic is an ATT test between g and the posterior mean of the
residual of the liability E(eDz,t), it will not have an inflated false-
Table 2. Average x
2 statistics for LT versus other approaches in simulated data.
c LogR LogR+Cov G+GxE LogRSub LT
OR
LBMI
OR
HBMI
0.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
0.06 11.27 11.27 9.69 10.60 12.11 1.15 1.10
0.07 14.61 14.61 12.86 13.72 15.77 1.17 1.12
0.08 18.43 18.43 16.52 17.32 19.97 1.20 1.13
0.09 23.11 23.12 21.04 21.66 25.03 1.23 1.15
0.10 27.88 27.89 25.73 26.21 30.34 1.25 1.17
0.11 33.45 33.47 31.15 31.38 36.48 1.28 1.19
0.12 39.77 39.80 37.51 37.24 43.46 1.31 1.20
0.13 45.92 45.95 43.64 42.89 50.29 1.34 1.22
0.14 52.74 52.78 50.55 49.11 57.79 1.37 1.24
0.15 59.63 59.68 57.89 55.60 65.55 1.39 1.26
For each statistic we display average results across 1,000,000 simulations, for various effect sizes c. All statistics are x
2(1 dof). Logistic regression with an interaction term
(G+GxE) values been converted from x
2(2 dof) to the equivalent x
2(1 dof) value. At an effect size of 0 all statistics give the expected value under the null. OR LBMI is the
odds ratio computed from cases with BMI=24. OR HBMI is the odds ratio for cases with BMI=35.
doi:10.1371/journal.pgen.1003032.t002
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extreme heteroscedasticity [32]. E(eDz,t) is the area under the tail
of a normal distribution and will therefore not have these
properties provided that the clinical covariate does not.
Logit disease model
The LT statistic assumes the same model used to generate the
data in the above experiments, and its increase in performance
over other methods may be driven by this fact. To examine this
possibility we conducted case-control study simulations under a
logit model as opposed to liability threshold model of disease used
above. We also performed simulations in which the LT parameters
were estimated from simulated epidemiological summary statistics.
In all cases, the LT statistic continued to outperform the other
methods by a similar margin (see Text S1 and Table S6 in File S1).
We conclude that leveraging external epidemiological data and
not the similarity of the generative model to the tested model
drives the increase in power.
Non-additive models
Our above simulations examine a range of alternatives
consistent with additivity on the liability scale. While data and
theory suggest that additivity explains most of the genetic variance
for a range of phenotypes [33], many researchers are interested in
a wider range of models involving gene x covariate interaction on
the liability scale. We simulated additional datasets in which we
added a positive or negative interaction term (see Text S1 and
Table S4 in File S1) and found that the relative performance of the
LT statistic depends on the direction of the interaction. Negative
interaction, such as the recently discovered coffee-GRIN2A
interaction in Parkinson’s disease [34], increases the power of
LT. Positive interaction, such those recently found for smoking
and lung cancer [35] decreases the power of LT (see Table S4 in
File S1). The G+GxE test outperformed the other statistical tests in
most of these simulations, although the LT statistic performed
better than G+GxE when the interaction term was negative.
Averaging across gene x covariate interactions in either direction,
LT outperformed LogR. This supports the use of LT instead of
LogR, even accounting for the possibility of gene x covariate
interaction on the liability scale.
Other statistical tests
Adjustment for informative covariates is not unique to genetics
and the problem of estimation from case-control data has received
considerable attention [10]. propose a weighted logistic regression
method (inverse-probability weighting) in the case of conditioning
on clinical variables in case-control ascertainment studies [9]. also
offer an efficient estimator for case-control ascertainment studies
in order to account for ascertainment-induced biases. In the case
of inverse-probability weighting, unbiased effect sizes are indeed
obtained, but it under-performed relative to the LT statistic in
simulations, with a 7% lower x
2 than the LT statistic in the
simulations from Table 2 when c=0.1 [12]. propose using a
retrospective likelihood to address case-control ascertainment
issues when conditioning on a covariates and implement a semi-
parametric test to incorporate the clinical covariates. In our case-
Figure 2. Power calculations for LogR, G+GxE, and LT approaches in simulated data. For each statistic we display power to attain
P,5610
28 based on 1,000,000 simulations of 3000 cases and 3000 controls, for various effect sizes c. The increase in power (ratio of y-axis values) for
LT versus LogR is 22.8% for c=0.1, and 23.0% when computing average power across all values of c. For c=0 the power was 5.0% for all statistics
when the P-value threshold is 0.05. G+GxE performs worse due to an extra degree of freedom.
doi:10.1371/journal.pgen.1003032.g002
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Text S1 in File S1). In the case of case-control-covariate designs
this semi-parametric test, as well as other previous approaches
[13,26], are not expected to improve power because they can not
leverage external epidemiological literature describing the clinical
covariates.
Mis-specification of model parameters
To investigate the sensitivity of the LT statistic to mis-specification
of model parameters, we performed additional simulations in which
we assumed model parameters that were different from those used to
simulate the data. We concluded that the LT statistic is robust to
deviations in model parameters (see Table S1 in File S1). However,
only analyses of empirical data can determine whether the liability
threshold model provides a good fit to real diseases.
Real datasets
Estimation of model parameters for real diseases. We
estimated parameters for each of the diseases using published
prevalence data as a function of the relevant covariates. For
example, for T2D we used prevalences 2%, 3%, 5%, 8%, 13%,
and 24% for BMIs 18, 21.5, 24.5, 27.5, 30.5, 35 respectively.
Using these data we fit the liability threshold model parameters so
as to minimize the squared error between the expected thresholds
and those specified by the model(see Methods). The values used to
fit the parameters and the sources of this information are given in
Text S1 in File S1. The inferred parameter values for each disease
studied are displayed in Table 3. These studies include both case-
control-covariate ascertainment as well as case-control ascertain-
ment strategies (see Table 4).
Type 2 diabetes datasets. Weapplied informedconditioning
to a case-control-covariate ascertained dataset of 5,051 T2D cases
and 3,529 controls from three Swedish cohorts (the Malmo
Preventive Project, Scania Diabetes Registry, and Botnia Study)
[16] genotyped on the Metabochip [36]. This study oversampled
low-BMI cases and younger cases, but did not explicitly match cases
and controls for BMI or age. The genotyped SNPs include 47 SNPs
identified by previous type 2 diabetes genome-wide association
studies (GWAS) [1]. T2D and BMI is a particularly compelling
example foranalysiswiththeLTstatistic,aswereportinTable S9of
ref. [1] that 23 of 29 T2D SNPs have higher effect size for low-BMI
versus high-BMI cases (P-value=0.0003; average odds ratios 1.182
versus 1.128, P-value for heterogeneity not significant for most
individual SNPs). (Also see [37], 29 of 36 T2D SNPs have higher
effect size with average odds ratios 1.13 versus 1.06 for low-BMI
versus high-BMI cases). Individuals are clinically diagnosed with
T2D if their fasting glucose exceeds a specific level. The similarity
between an underlying liability and fasting glucose exceeding a
threshold further motivates the use of an LT model to analyze T2D.
We compared association statistics over these T2D data using four
approaches: LogR, LogR+Cov, logistic regression with an interaction
term (G+GxE), and LT. Logistic regression without high-BMI cases
(LogRSub) was not included since it contains strictly fewer individuals
and its performance is not expected to exceed LogR. The G+GxE
test underperformed relative to other methods in all datasets due to its
extra degree of freedom. This is expected since the SNPs were
discovered with a marginal test, and are therefore less likely to have
gene x covariate interactions on the liability scale. Results are
displayed in Table 4, Table5, and Table S8in File S1and we see that
the sum of x
2 statistics across all loci is 51% higher for LT than LogR.
Table 3. Inferred covariates and effect sizes on the liability scale.
Disease
%Variance
Explained LT Model for Q
T2D (Metabo) BMI=14%, age=6% 0.08*(BMI-26.5)+0.029*(age-50)-1.38
BMI=15% 0.08*(BMI-26.5)-1.44
age=9% 0.029*(age-50)-1.28
T2D (MEC) BMI=14%, age=4% 0.08*(BMI-26.5)+0.029*(age-50)-1.38
BMI=15% 0.08*(BMI-26.5)-1.44
age=5% 0.029*(age-50)-1.28
PC age=14% 0.049*(age-50)-2.49
LC age=2%,smoking=76% 0.03*(age-50)+2.6*(smoking-0.25)-3.06
age=17% 0.04*(age-50)-3.30
smoking=51% 2.04*(smoking-0.25)-2.37
BC age=8% 0.032*(age-50)-2.26
RA age=6%, sex=2% 0.022*(age-50)+0.32*(sex-0.5)-2.46
age=6% 0.022*(age-50)-2.46
sex=2% 0.32*(sex-0.5)-2.34
ESKD age=15% 0.02*(age-50)-2.08
AMD age=17%, BMI30=5% 0.03*(age-50)+0.61*(BMI30-0.30)-2.00
age=11% 0.04*(age-50)-2.10
BMI30=6% 0.35*(BMI30-0.30)-1.72
LT model is the liability threshold model for each disease with parameters estimated using the LTPub method. For diseases with multiple covariates, models with all
covariates and each covariate separately are given. %Variance Explained is the fraction of variance explained on the liability scale in the study data for each of the
covariates in each of the diseases when all covariates are used in the model, and is specific to the distribution of covariates in each particular study. BMI30 is a binary
variable, which is 1 if an individual’s BMI is greater than 30 and 0 otherwise. Type 2 diabetes (T2D), prostate cancer (PC), lung cancer (LC), breast cancer (BC), rheumatoid
arthritis (RA), end-stage kidney disease (ESKD), and age-related macular degeneration (AMD).
doi:10.1371/journal.pgen.1003032.t003
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individuals with high BMI. The T2D LT models also use age as a
covariate and in the LTPub estimation method age and BMI were fit
jointly (see Methods). We reran the LTPub estimation fitting BMI
and age separately and found the improvements over LogR to be
32% and 18% respectively.
It is of interest to include non-European ancestries in studies of
T2D, because non-Europeans have higher T2D risk [38,39]. We
examined the performance of the same six statistics over of 6,142
cases and 7,403 controls genotyped at 19 known associated SNPs
from the Multiethnic Cohort (MEC) (African Americans, Latinos,
Japanese Americans, Native Hawaiians, and European Americans)
[38]. A potential concern is that risk SNPs identified in Europeans
may not be associated in other populations due to different LD
patterns, however, previous analyses have demonstrated that these
19 SNPs are consistently associated to T2D in all MEC ancestries
[38]. Results are displayed in Tables 4–5 and Table S9 in File S1.
We see that application of LT attains 26% higher x
2 statistics than
LogR. We reran the LTPub estimation fitting BMI and age
separately and found the improvements over LogR to be 20% and
3% respectively.
The Metabochip study included a large number of low-BMI
cases as part of their ascertainment strategy whereas the MEC
study ascertained randomly with respect to BMI. Including low-
BMI cases increases the power of the Metabochip study since odds
ratios estimated from the population of low-BMI individuals will
be larger [16] (Table S9 of ref. [1]). This is predicted by the
liability threshold model since low-BMI cases require additional
factors (i.e. genetic factors) to exceed the threshold. In our
simulations (see Text S1 and Table S2 in File S1) the improvement
of LT over LogR was even greater with this ascertainment strategy
than it was in a standard case-control ascertainment strategy.
Thus, this strategy gives even greater performance of the LT
statistic relative to LogR because the low-BMI cases will be up-
weighted relative to the high-BMI cases. This is likely the cause of
the better performance of LT in Metabochip compared to the
MEC dataset.
For each T2D dataset, we simulated 100,000 datasets with the
same sample sizes, covariates, and case-control status as the real
datasets. We simulated a causal variant with effect size 0.1 and
minor allele frequency 0.1 under the LT model for T2D and
computed statistics for LT and LogR. The percent improvements
were 40%+21% for Metabochip and 22%+6% for MEC similar
to those in the real datasets (see Table S5 in File S1).
Prostate cancer dataset. We applied informed conditioning
to a case-control-covariate ascertained dataset of 10,501 prostate
cancer cases and 10,831 controls (with 7 of 8 cohorts age-matched)
from the NCI Breast and Prostate Cancer Cohort Consortium
(BPC3) that were genotyped at 39 SNPs identified by previous
prostate cancer GWAS [40]. We previously reported that 32 of 39
SNPs had a higher odds ratio for early-onset cases versus late-onset
cases (Table S3 of ref. [40]), which is unlikely to be due to chance
(P,0.0001) and motivates the question of whether informed
conditioning of prostate cancer might increase power.
We compared association statistics using four approaches:
LogR, LogR with age as covariate, logistic regression with an
interaction term (G+GxE), and LT. As was the case for T2D,
G+GxE underperformed relative to the other methods due to its
extra degree for freedom. Results are displayed in Tables 4–5 and
Tables S10–S11. We see that application of LT attains 7% higher
sum of x
2 statistics than LogR and that the odds ratios computed
from early-onset cases are greater than those computed from late-
Table 4. Summary information for all datasets.
Disease Ascertainment Cases Controls SNPs ORL.ORH LTPub.LogR
T2D (Metabo) Case-Control-Covariate 5051 3529 47 37 37
T2D (MEC) Case-Control-Covariate 6142 7403 19 15 16
PC Case-Control-Covariate 10501 10831 39 32 30
LC Case-Control-Covariate 6952 6661 16 13 12
BC Case-Control-Covariate 9619 12244 20 12 11
RA Case-Control 5024 4281 21 16 15
ESKD Case-Control 1030 1025 1 1 1
AMD Case-Control-Covariate 473 1103 2 2 2
SUM n/a 37840 40416 165 128 128
ORL.ORH is the number of SNPs in which the odds ratio of low risk cases (e.g. low-BMI) is greater than then odds ratio computed from the high risk group (e.g. high-
BMI). LTPub.LogR is the number of SNPs in the dataset for which LTPub exceeded the LogR statistic. There are 9 SNPs shared between the two T2D sets. In total there
are 157 unique SNPs and 115 unique SNPs with LTPub.LogR. Type 2 diabetes (T2D), prostate cancer (PC), lung cancer (LC), breast cancer (BC), rheumatoid arthritis (RA),
end-stage kidney disease (ESKD), and age-related macular degeneration (AMD).
doi:10.1371/journal.pgen.1003032.t004
Table 5. Summary statistics across all datasets.
Disease LTPub LogR LogR+Cov
LTPub vs
LogR
T2D (Metabo) 369.7 244.05 252.23 +51%
T2D (MEC) 402.86 320.08 400.89 +26%
PC 1912.88 1787.61 1844.40 +7%
LC 416.95 359.64 331.28 +16%
BC 395.16 390.86 386.83 +1%
RA 511.31 470.91 466.11 +9%
ESKD 188.38 137.80 134.70 +37%
AMD 185.6 159.38 110.33 +16%
The sum of each of the test statistics across all of the SNPs in each of the
diseases. LTPub vs LogR is the % increase of LTPub compared to LogR. It has a
median value of 16%. Type 2 diabetes (T2D), prostate cancer (PC), lung cancer
(LC), breast cancer (BC), rheumatoid arthritis (RA), end-stage kidney disease
(ESKD), and age-related macular degeneration (AMD).
doi:10.1371/journal.pgen.1003032.t005
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significant effect on these tests. The age information in this study
is age at onset and we therefore repeated the analysis using
E(eDz,t)={c(t{ t t){m in cases (see Methods). This increased the
sum of x
2 statistics from 1912.88 to 1925.65.
Werepeatedtheanalysiscomputingassociationstatisticsseparately
for each of the eight BPC3 cohorts and performing a meta-analysis
across cohorts using inverse variance weighting to combine test
statistics [41]. Results were broadly similar, with a 7% increase in the
sum of x
2 statistics of LT compared to LogR. However, one
difference is that LogR with age as covariate produced a 1.3%
increase in x
2 statistics in the combined analysis (both with and
without study as a covariate) but a 2.3% decrease in x
2 statistics in the
meta-analysis. We sought to understand this difference by comparing
performance separately for each cohort. We determined that LogR
with age as covariate performs similarly to LogR if cases and controls
are age-matched, performs worse than LogR if controls are much
younger, slightly older or much older than cases, but performs better
if controls are slightly younger than cases—as in the HPFS cohort
and in the combined analysis. LogR with age as covariate performs
better in the latter case because age-adjusted case-control phenotype
has a more extreme value in younger cases than in older cases,
mimicking the posterior mean quantitative trait phenotype used in
the LT statistic. The effect of conditioning covariate in LogR is a
complex function of ascertainment strategy, effect size, and the
distribution in the cohort, and should not be viewed as a method that
improves power in the general case [9,10,11].
For the prostate cancer dataset, we simulated 100,000 datasets
with the same sample size, covariates, and case-control status as
the real dataset. We simulated a causal variant with effect size 0.07
and minor allele frequency 0.05 under the LT model and
computed statistics for LT and LogR. The percent improvement
was 6%+3%, similar to that in the real dataset (see Text S1 and
Table S5 in File S1).
Other datasets. In addition to T2D and prostate cancer, we
examined lung cancer [42,43] with age as a covariate, breast cancer
[44,45] with age as a covariate, rheumatoid arthritis [46] with age
and sex as covariates, age-related macular degeneration [47] with
age as a covariate, and end-stage kidney disease [48] (ESKD) with
age as a covariate (Tables 4–5 and Tables S5,S11–S15). The breast-
cancer, lung-cancer, and age-related macular degeneration studies
are matched case-control-covariate ascertained, and the rheuma-
toid arthritis and ESKD studies are case-control ascertained. The
parameters for the LTPub model were set according to published
prevalence studies for the appropriate covariates and diseases (see
Text S1 in File S1). In each case we compared the relative
performance of the LT statistic to the standard association test
statistics over known associated SNPs with results presented in
Tables 4–5 and Tables S11–S15. The LT statistic improved 16%
for lung cancer, 1% for breast cancer, 9% for rheumatoid arthritis,
37% for end-stage kidney disease, and 16% for age-related macular
degeneration (see Table S5 in File S1). Across all datasets 115 out of
157 SNPs had higher odds ratios in the low risk group as expected
from the LT model. The age information in the breast cancer study
is age at onset and we therefore repeated the analysis using
E(eDz,t)={c(t{ t t){m in the cases (see Methods). This decreased
the sum of x
2 statistics from 395.16 to 393.39.
Averaging across the eight datasets analyzed, the LT approach
we propose attained a median improvement of 16% and mean
improvement of 20% as compared to the commonly used LogR
method, with an improvement for 115 of 157 SNPs (P-
value=1610
29). To show that relative improvement of LT is
not solely due to SNPs with large values of LogR, we computed
the sum of LT and LogR for the SNPs in the lower 50% of LogR
for each disease excluding the single SNP of ESKD. The LT
statistic had a 15% median improvement and an 18% mean
improvement over LogR for these lower 50% SNPs. We also ran
permutations to show that the gains of the LT relative to LogR
require the correct covariate information and that genotype and
covariate are correlated for known loci, as predicted by the liability
threshold model (see Text S1 in File S1) and any penetrance
model where genotype and clinical covariate affect outcome [10].
T2D and lung cancer are both affected by clinical covariates
(BMI and smoking status) that are partly genetically driven. In
such instances, LT modeling of the covariate will generally
increase power to detect SNPs whose primary association is to the
disease, and reduce power to detect SNPs whose primary
association is to the covariate with secondary association to the
disease. In light of this, LT modeling of the covariate is our
recommended strategy, since SNPs whose primary association is to
the covariate are best discovered via separate studies of association
to the covariate trait. Following this strategy, we used both BMI
and age as covariates for T2D. We note that the T2D SNPs tested
include one locus (FTO) which has a primary association to BMI
with induced secondary association to T2D [49]. As expected, LT
performed poorly at FTO SNPs (Table S8, S9 in File S1). We
elected to include FTO SNPs in our computation of %
improvement in order to avoid overstating our results, but we
believe it would be technically appropriate to exclude these SNPs
from this computation, since they would be best discovered by a
separate study of association to BMI.
Inthecaseoflung cancer,ifthe goalisto identifylungcancer SNPs
(rather than smoking SNPs) we recommend including both age and
smoking as covariates. However, our task of evaluating the LT model
for lung cancer was complicated by the fact that many known lung
cancer loci have a primary association to smoking with a secondary
(less statistically significant) association to lung cancer [50,51].
Therefore, we conservatively report the improvement for using age
as a covariate only. However, we believe it would be technically
appropriate to exclude smoking SNPs from the computation and
report the larger improvement for age and smoking as covariates for
the remaining SNPs. Therefore, we reran the lung cancer data on the
subset of five SNPs that do not havea primary association to smoking
status, and fit both age and smoking status with LTPub to get
Q=0.030*(age-50)+2.59*(smoking-0.25)23.06, where smoking is
status as a smoker or non-smoker. Age described 2% of the variation
on the liability scale and smoking status described 76%. The
improvement of LT over LogR was 30% for age and smoking, 27%
for age only, and 11% for smoking status only.
False-positive rate and correct null distribution
For each disease we permuted the genotypes of the individuals,
keeping the case-control and covariates fixed 100,000 times. We
reran the LT statistic on each permutation using the same LTPub
parameters for each disease as above, and verified that LT had the
appropriate 5% type 1 error rate at each SNP and lGC =1.00.
Additionally, we computed LT statistics on the complete Women’s
Genome Health Study (WGHS) age-related macular degeneration
GWAS dataset of 339,596 SNPs [52]. There were 5.00% of tests
with P-value,0.05 and 1.02% for P-value,0.01. Furthermore the
Kolmogorov-Smirnov test [31] with a x
2(1 dof) distribution was
not significant (P-value=0.26), nor was the K-S test restricted to
the tail with LT x
2.3.84 (P-value=0.15).
Discussion
We have shown that informed conditioning on clinical
covariates in association studies with case-control-covariate or
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the simulations and empirical datasets analyzed here. The gain in
power varies across diseases and is a function of the proportion of
variance on the liability scale explained by the covariate(s), the
disease prevalence, and the ascertainment strategy. We note that the
increase in power will often exceed the increase in x
2 statistics. For
example, a GWAS with 5000 cases and 5000 controls has 43.7%
power at P-value threshold 5610
28 to detect a SNP with a minor
allele frequency of 20% and an odds ratio of 1.2. The power
increases to 59.8% (a.36% increase in power, in the sense that
.36% morevariants willbe discovered) when increasing x
2 statistics
by 16%, which is similar to the median increase in x
2 statistics that
we observed in our empirical studies. Additional significant gains in
power, particularly under the LT approach, are possible by
collecting cases at phenotypic extremes [16,53,54,55,56,57], taking
care to check for SNPs associated with covariate as opposed to the
disease [10]. The use of genetic covariates in the LT framework may
also significantly increase the power of association studies. In that
context we recommend a different method for estimating LT model
parameters [26]. The LT approach is also applicable to data
obtained from high throughput sequencing studies [16].
Thus, there is a very strong motivation for applying the
approach we have described to type 2 diabetes, prostate cancer,
lung cancer, age-related macular degeneration, and end-stage
kidney disease (for which the LTPub parameters in Table 3 can be
used), as well as for other diseases with analogous effects of clinical
covariates on genetic risk (for which LTPub can be used to
estimate parameters). For T2D and prostate cancer alone, we
identified 29 recent studies published in Nature Genetics (see Text S1
in File S1) that would benefit from application of our method.
Notably, our empirical improvements are in line with the
improvements that would have been expected based on SNP
and covariate effect sizes in these same datasets. In the case of
diseases with genetically driven covariates (e.g. BMI in T2D) we
recommend using all available covariates unless the goal is to
identify SNPs whose primary association is to the covariate. There
are many other diseases with important clinical covariates where
informed conditioning may prove useful [58,59,60]. Recent
studies of age-related macular degeneration [61] and gout [62]
found increased odds ratios estimated from younger cases and
genetic associations to age of onset, which is consistent with the LT
model.
We caution against the use of standard conditioning approaches
(LogR+Cov) in case-control ascertained studies, which can
increase or decrease power as a function of covariate effect size
and disease prevalence [8,10,26]. The relationship between
modeling disease on the liability threshold and dichotomous scale
has been examined by [23] as well as [24,25] in the context of
computing the area under the receiver operator curve (AUC),
estimating risks, and the distribution of disease in a population. A
recent study of Clayton has examined the use of covariates in case-
control ascertained association studies and shown that a reweight-
ing method (such as ours) can increase power [13]. This paper
discusses the issue of power loss from conditioning [8] in logistic
regression and states, ‘‘the loss of power resulting from the use of
stratified tests can be avoided by matching in the design of case-
control studies’’. We have shown that by including information
from external epidemiological information, it is possible to not
only avoid a power loss, but to achieve substantial power gain in
matched case-control-covariate studies. The paper also states, ‘‘the
strategy of ignoring other known disease susceptibility loci and risk
factors when testing for new associations with complex disease, for
example in genome-wide association studies, is justifiable, but only
when effects combine additively on the logistic scale.’’ While
ignoring other risk factors is justifiable when testing under a
retrospective logit model, we have demonstrate here, that for
diseases with non-infinitesimal prevalence, and assuming gene
environment independence, it is possible to achieve power gains
even when the disease model is additive under a logit model. This
was also shown in the work of [12] under a prospective logit
model. We discuss additional approaches to analysis case-control
ascertained data in Text S1 in File S1.
We designed the LT method for effects that are additive on the
liability scale, which are hypothesized to account for the majority
of genetic variation across a range of complex phenotypes [33].
We have shown empirically that it also behaves well under the
standard additive logit model. In the presence of gene x covariate
interaction it alternatively loses or gains power depending upon
the direction of the interaction, but the method’s increase in power
does not rely on the presence of interaction. When interaction is
present, other methods, such as logistic regression with an
interaction term (G+GxE), may be more powerful. However, the
LT statistic outperformed commonly used tests such as LogR on
average in simulations of gene x covariate interaction (Table S4 in
File S1), and remains our recommended approach after account-
ing for the possibility of such interactions. We note that when there
is no true gene x covariate interaction on the liability scale, but
individuals are ascertained based on phenotype, there will be an
induced correlation between clinical covariate and genotypes
associated with phenotype. Furthermore, there may be evidence of
GxE interaction on the odds ratio scale and we therefore caution
against inferring a biological mechanism of interaction when the
data are consistent with additivity on the liability scale.
Meta-analysis is easily handled in the context of the liability
threshold framework. Summary statistics are typically combined
using odds ratios and standard errors. The LT statistics returns
effect sizes on the liability scale and standard errors. Since these
are easily converted to odds ratios (see Text S1 in File S1), and a
standard inverse variance weighting can be used to combine
results on either scale to generate a meta-analysis statistic.
Furthermore, since odds ratios are a function of covariate
ascertainment (e.g. if young cases are oversampled), meta-analysis
on the liability scale maybe able to provide more robust estimates
of effect size. Replication of results works as normal, additional
cases and controls are collected, genotyped, and tested for
association. If covariate information is not available in the
replication set a standard LogR test is used.
The LT statistic uses covariates to increase power. We assume
that the LT model parameters estimated from epidemiological
data, as well as the values of the covariates measured in the study,
are reasonably accurate. Under inaccurate estimation of model
parameters our method will have reduced power relative to its
power with accurate model parameters, but it will still have the
correct null distribution. In simulations, mis-specifying the
parameters by a moderate amount produced almost no change
in power and mis-specifying the parameters by a large amount (up
to 100%) still performed at least as well as logistic regression with
no conditioning in all cases examined (see Text S1 in File S1).
Accounting for uncertainty in the data from the epidemiological
literature may further improve the increase in test statistic beyond
the 16% observed in this analysis. Additional covariates (e.g.
principal component covariates) may be needed to prevent false
positives [27,63]. These are easily handled by the LT statistic and
included in the linear regression after the posterior means are
computed (see Text S1 in File S1). When a genetically driven
covariate is correlated to the phenotype (e.g. BMI in T2D),
including that covariate in the LT model will alter the power to
find SNPs related to phenotype through the covariate (see Text S1
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in the T2D Metabochip study), there exists the theoretical
possibility of misclassifying a covariate (BMI) association as a
phenotype (T2D) association [49], because the posterior means
may be correlated with BMI. Our recommendation is to check this
by testing for association to the covariate (BMI) explicitly. A more
conservative approach is to use BMI as a covariate after posterior
means are computed, but some of the increase in power may be
lost.
When conducting an association study where known clinical
factors alter disease risk, the gain in power of the LT statistic is
function of the number of individuals with available covariate
information. For example, in the DIAGRAM dataset all 31
cohorts had BMI information and 20 had age at diagnosis
information, thus the gain in power possible from the LT method
will be nearly maximal [1]. If the increase in x
2 is 16%, then an
individual with a covariate provides the same power as 1.16
individuals with no covariate. Researchers should therefore
carefully weigh the cost of collecting covariates when designing
studies since it may provide a more cost effective way to
substantially increase power than genotyping more individuals.
In cross-sectional studies when data are randomly ascertained
with respect to both case-control status and clinical covariate, the
LT statistic and LogR+Cov are expected to perform similarly and
our recommendation is to use LogR+Cov. In case-control studies
of high prevalence diseases when clinical covariates are randomly
ascertained, but cases are oversampled relative to their prevalence
in the population, the LT statistic will slightly outperform
LogR+Cov and our recommendation is to use the LT statistic.
In case-control diseases of low prevalence, or in case-control-
covariate studies when clinical covariates are non-randomly
ascertained the LT statistic will substantially outperform Log-
R+Cov (which may often lose power relative to LogR) and our
recommendation is to use the LT statistic. As described above, the
LT statistic also outperforms other methods. In summary,
informed conditioning on clinical covariates has a large potential
to increase the power of case-control association studies and
identify new risk variants.
Web resources
LTSOFT software: http://www.hsph.harvard.edu/faculty/alkes-
price/software/
Supporting Information
File S1 Supporting information.
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